AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05635838
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT06137300
Drug: Urinary kallidinogenase for injection
RxNorm normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary kallidinogenase 0.15PNA once daily for 7 days.
Trial: NCT05144542
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smoke usual brand of cigarettes
Trial: NCT05144542
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vape e-cigarettes
Trial: NCT04685473
Drug: T-1101 (Tosylate)
RxNorm normalized name: T-5224
DrugBank: FT-1101 (DB17553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-1101 (Tosylate) Capsule
Trial: NCT06247540
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Receive PO
Trial: NCT05153408
Drug: osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib tablets for oral administration
Trial: NCT05153408
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion of carboplatin
Trial: NCT05153408
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion of pemetrexed
Trial: NCT04918589
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 grams of tranexamic acid (30 mL of 100 mg/mL solution) diluted in 10 mL of normal saline
Trial: NCT05089305
Drug: Ozone plasma
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).
Trial: NCT04841343
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone in sinus
Trial: NCT06699602
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: cemiplimab IV flat
Trial: NCT06699602
Drug: Fianlimab
RxNorm normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fianilmab IV flat
Trial: NCT06613100
Drug: Xaluritamig
RxNorm normalized name: Xaluritamig
DrugBank: Xaluritamig (DB18137)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT00000110
Drug: dietary fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05507606
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: osimertinib 80mg/d
Trial: NCT05507606
Drug: Bevacizumab Biosimilar IBI305
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years
Trial: NCT05507606
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC5, d1; was stopped after 4 cycles
Trial: NCT05507606
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
Trial: NCT06388720
Drug: Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical sequential treatment of Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml.
Trial: NCT04516902
Drug: Lysergic Acid Diethylamide
RxNorm normalized name: Lysergic acid diethylamide
DrugBank: Lysergic acid diethylamide (DB04829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A moderate dose of 100 μg LSD will be administered.
Trial: NCT04516902
Drug: 3,4-methylenedioxymethamphetamine
RxNorm normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A moderate dose of 100 mg MDMA will be administered.
Trial: NCT05689827
Drug: Ethyl methyl hydroxypyridine succinate + Meldonium
RxNorm normalized name: 2-ethyl-6-methyl-3-hydroxypyridine
DrugBank: Meldonium (DB13723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)
Trial: NCT05748600
Drug: Dexpramipexole Dihydrochloride
RxNorm normalized name: Pramipexole Dihydrochloride
DrugBank: Dexpramipexole (DB15130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of dexpramipexole tablet
Trial: NCT00000960
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05593601
Drug: Neomycin
RxNorm normalized name: Neomycin
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
Trial: NCT04853797
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg oral Ivabradine.
Trial: NCT05669885
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will be allocated to receive oral administration of 100 mg sildenafil.
Trial: NCT06202261
Drug: Paclitaxel for injection (albumin-bound)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: It is an anti-microtubule chemotherapy drug
Trial: NCT06202261
Drug: Fulvestrant injection
RxNorm normalized name: Fulvestrant Injection
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol
Trial: NCT06202261
Drug: Vinorelbine tartrate injection
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine is an anti-tumor drug of vinca alkaloids.
Trial: NCT06202261
Drug: Eribulin mesylate injection
RxNorm normalized name: Eribulin Mesylate Injection
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.
Trial: NCT06202261
Drug: gemcitabine hydrochloride for injection
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
Trial: NCT05420012
Drug: Vericiguat
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
Trial: NCT05717738
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8mg; p.o.; q.d.
Trial: NCT05717738
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
Trial: NCT05717738
Drug: Bevacizumab Biosimilar IBI305 plus sintilimab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
Trial: NCT05717738
Drug: Bevacizumab plus Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
Trial: NCT05717738
Drug: apatinib plus camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
Trial: NCT05717738
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg; p.o. bid
Trial: NCT05717738
Drug: Donafenib
RxNorm normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg; p.o. bid
Trial: NCT05717738
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 mg; p.o.; q.d.
Trial: NCT05396118
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
Trial: NCT04541823
Drug: Desﬂurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
Trial: NCT04541823
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
Trial: NCT05278793
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate 200mg oral
Trial: NCT06527300
Drug: NHWD-870 HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered P.O.
Trial: NCT06070610
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550
Trial: NCT06070610
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Soft capsules
Trial: NCT06070610
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Film-coated tablets
Trial: NCT05870475
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.
Trial: NCT05870475
Drug: Pegylated interferon α-2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.
Trial: NCT00486980
Drug: Peramivir 150mg
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00486980
Drug: Peramivir 300mg
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05465174
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT05465174
Drug: Tovorafenib
RxNorm normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT05211050
Drug: Sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 min infusion of 4 mg sumatriptan.
Trial: NCT05211050
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 min infusion of isotonic saline (placebo).
Trial: NCT04661137
Drug: Selinexor 60 MG
RxNorm normalized name: selinexor 60 MG
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor 60 mg PO on days 1, 8 and 15
Trial: NCT04661137
Drug: Selinexor 80 MG
RxNorm normalized name: selinexor 80 mg/week (20 mg x 4) ORAL TABLET
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor 80 mg PO on days 1, 8 and 15
Trial: NCT04661137
Drug: Selinexor 100 MG
RxNorm normalized name: selinexor 100 mg/week (20 mg x 5) ORAL TABLET
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor 100 mg PO on days 1, 8, 15 and 22
Trial: NCT04661137
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 56 mg/m2 IV on days 1, 8 and 15
Trial: NCT04661137
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg PO daily for 21 days
Trial: NCT04661137
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on
Trial: NCT04661137
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22
Trial: NCT04679389
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered orally or enterally
Trial: NCT05152472
Drug: Atezolizumab 1200 mg
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (Intravenous administration)
Trial: NCT05152472
Drug: Imatinib 400 MG
RxNorm normalized name: imatinib 400 MG
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (Per os)
Trial: NCT05980026
Drug: oral omega-3 fatty acids supplementation
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral omega-3 fatty acids supplementation
Trial: NCT06671379
Drug: SHR-A2009 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously
Trial: NCT06671379
Drug: platinum-based dual-agent chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously
Trial: NCT06560268
Drug: Sevoflurane; In our study, the effects of sevoflurane in different FGFs administered in children undergoing strabismus surgery on EA and anesthetic agent consumption will be investigated.
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-flow anaesthesia is generally adminstered as nitrogen wash-out, a period of higher flow rate in combination with a high vaporizer setting for initial saturation, and subsequent reduction of fresh gas flow and adjustment of the vaporizer to maintain the desired end-tidal anesthetic agent concentration (Etaa).In the initial wash-in phase, the vaporizer setting is adjusted to 6% for desflurane and 2.5-3% for sevoflurane, with FGF=4 L/min, until the Etaa concentration is 1-1.3 MAC. In another method, the vaporizer setting is adjusted to 12-18% for desflurane and 6-8% for sevoflurane, with FGA=1 L/min. Reducing the FGF during the wash-in period prevents unnecessary depth of anesthesia and reduces the consumption of inhalational anesthetics. In LFA using minimal FGF (250-500 mL/min), if the vaporizer is turned off 10-15 min before the end of the operation and the FGF is not changed, the inhaled anesthetic agent concentration gradually and slowly decreases to zero.
Trial: NCT05148494
Drug: Pico-Salax
RxNorm normalized name: SALIX
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard pre-op application, see arm description
Trial: NCT04776369
Drug: Lidocaine IV
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single-bolus of lidocaine IV 4 mg/kg
Trial: NCT04776369
Drug: Magnesium Sulfate Injection
RxNorm normalized name: magnesium sulfate Injection
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single-bolus of magnesium sulfate IV 30 mg / kg
Trial: NCT05652660
Drug: ARV-471
RxNorm normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT05008510
Drug: Sacituzumab Govitecan-hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan-hziy
Trial: NCT05008510
Drug: Sabizabulin/Sacituzumab govitecan-hziy Combo
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sabizabulin/Sacituzumab govitecan-hziy Combo therpy
Trial: NCT00994916
Drug: 3,4 diaminopyridine
RxNorm normalized name: 3,4 diaminopyridine
DrugBank: Amifampridine (DB11640)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3,4 diaminopyridine up to 80 mg daily in divided doses
Trial: NCT00002408
Drug: Crofelemer
RxNorm normalized name: Crofelemer
DrugBank: Crofelemer (DB04941)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00548821
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00053612
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05581576
Drug: Pitolisant
RxNorm normalized name: pitolisant
DrugBank: Pitolisant (DB11642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
Trial: NCT06184581
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
Trial: NCT06184581
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
Trial: NCT06058234
Drug: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
DrugBank: Amyl acetate (DB15927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
Trial: NCT06531525
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
Trial: NCT06531525
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.
Trial: NCT06531525
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.
Trial: NCT04841668
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)